Genomic Based Solutions for Your Immuno-oncology Drug Development Needs
Genomics-based biomarker approach
Wendell Jones, Ph.D., Principal Bioinformaticist and Scientific Advisor, Q2 Solutions
Patrick Hurban, Ph.D., Senior Director and Global Head, Translational Genomics, Q2 Solutions
Comprehensive genomic strategies are needed to support immuno-oncology clinical development programs. Genomics is a key tool that such programs can embrace to help understand and elucidate the individual response signatures to immuno-oncology therapies. Given the advent of a myriad of combination studies with additional biological complexity, genomics can play a key role in understanding T-cell functions and tumor factors that contribute to efficacy, safety and resistance outcomes. Such applications can include baseline assessments prior to therapy to drive patient selection but also longitudinal sampling to monitor treatment response by examining the genetic signatures over time.
Complete the form below to access this insight brief